


Meeting Overview

Category	Number
Votable Meetings	39
Meetings Voted	39
Proxy Contests Voted	0
Meetings with Against Management Votes	22
Meetings with Against ISS Votes	8


Comparison of Meetings Voted



With 39 meetings available to vote during the period, 39 were voted, equating to approximately 100% of the votable meetings with close to 0% unvoted.


Alignment with Management

- Comparing vote cast alignment with management recommendations highlights similarities and differences between your governance philosophies and the investee's approach to key corporate governance issues.
- The votes cast on Kieger AG ballots during the reporting period are aligned with management recommendations in 91% of cases, while the ISS Benchmark Policy recommendations are at 92% alignment with management recommendations.




Votes Cast on Management Proposal Categories

- › Comparing the votes cast in support of Management proposals, ISS Benchmark Policy recommendations across the major proposal categories provides insight into the positioning of votes on proposals submitted by Shareholders against the aforementioned benchmarks.
- › Votes cast during the reporting period were least in line with management on Miscellaneous matters, where only 0% of votes followed management recommendations.
- › Across categories, votes cast on management proposals show the closest alignment to the ISS Benchmark Policy guidelines.



Votes Cast on Shareholder Proposal Categories

- › Comparing the votes cast in support of Shareholder proposals, ISS Benchmark Policy recommendations across the major proposal categories provides insight into the positioning of votes on proposals submitted by Shareholders against the aforementioned benchmarks.
- › Votes cast during the reporting period show the highest level of support for shareholder proposals related to Environmental, at 100% and the lowest level of support for shareholder proposals related to Director Related, E&S Blended, with 0% of proposals supported.
- › Across categories, votes cast on shareholder proposals show the closest alignment to the ISS Benchmark Policy guidelines.



Sector	% Meetings Voted	% of Companies with ISS Governance QualityScore of 8, 9 or 10 ¹	% of Votes Cast Against Management	% of Votes Cast Against ISS Benchmark Policy
Communication Services	N/A	N/A	N/A	N/A
Consumer Discretionary	N/A	N/A	N/A	N/A
Consumer Staples	N/A	N/A	N/A	N/A
Energy	N/A	N/A	N/A	N/A
Financials	N/A	N/A	N/A	N/A
Health Care	100%	21%	9%	3%
Industrials	N/A	N/A	N/A	N/A
Information Technology	N/A	N/A	N/A	N/A
Materials	N/A	N/A	N/A	N/A
Real Estate	N/A	N/A	N/A	N/A
Utilities	N/A	N/A	N/A	N/A
TOTALS	100%	21%	9%	3%

Region	% Meetings Voted	% of Companies with ISS Governance QualityScore of 8, 9 or 10 ¹	% of Votes Cast Against Management	% of Votes Cast Against ISS Benchmark Policy
Africa	N/A	N/A	N/A	N/A
Americas	100%	27%	7%	2%
Antarctica	N/A	N/A	N/A	N/A
Asia	N/A	N/A	N/A	N/A
Europe	100%	8%	13%	4%
North America	N/A	N/A	N/A	N/A
Oceania	N/A	N/A	N/A	N/A
Unknown	N/A	N/A	N/A	N/A
TOTALS	100%	21%	9%	3%


¹Percentages based on the universe of holdings within the ISS Governance QualityScore coverage universe.

Largest Portfolio Positions with High Governance Risk

The table below highlights the top 15 largest positions for those companies deemed high-risk, as indicated by an ISS Governance QualityScore between 8 and 10. Companies are only shown if they held a meeting during the reporting period.

Company	Ticker	Estimated Position Value (USD) ¹	ISS Governance QualityScore	Board Structure	Compensation/Remuneration	Shareholder Rights & Takeover Defenses	Audit & Risk Oversight
Eli Lilly and Company	LLY	14.9 M	8	6	5	9	9
Thermo Fisher Scientific Inc.	TMO	10.9 M	8	8	10	1	1
UnitedHealth Group Incorporated	UNH	8.8 M	8	6	9	1	10
Boston Scientific Corporation	BSX	8.6 M	8	7	5	8	10
BeiGene Ltd.	6160	3.6 M	8	5	10	6	9
Globus Medical, Inc.	GMED	3.2 M	10	9	6	10	7
Bachem Holding AG	BANB	2.3 M	9	9	9	6	7
Align Technology, Inc.	ALGN	1.4 M	8	5	9	8	2

Portfolio Risk by ISS Governance QualityScore



21%² of the companies within your portfolio that held meetings during the reporting period are high risk, falling within the ISS Governance QualityScore range of **10** through **8**.

ISS Governance QualityScore is a data driven scoring and screening solution designed to identify governance risk within companies. ISS Governance QualityScore is derived from publicly disclosed data on the company's governance practices. Scores indicate decile rank relevant to index or region. For more information on ISS Governance QualityScore, visit <https://www.issgovernance.com/solutions/iss-analytics/qualityscore/>.

¹Estimated values are based on shares held on record date for the company's most recently held meeting during the reporting period. Please contact your ISS Client Service Team with any questions related to how this value is calculated.

²Percentages based on the universe of holdings within the ISS Governance QualityScore coverage universe.

Contested Meetings Overview

There is no applicable content to display for the reporting period.

*Values are based on shares held on record date for the company's meeting held during the reporting period. Please contact your ISS Client Service Team with any questions related to how this value is calculated.

Contested Meetings & Largest Portfolio Positions with High Governance Risk Meeting Details

Company	Ticker	Meeting ID	Meeting Date	Proposal #	Proposal Text	Management Recommendation	Policy Recommendation	Vote Instruction	Rationale
BeiGene Ltd.	6160	1940732	28-Apr-2025	1	Change Jurisdiction of Incorporation from Cayman Islands to Switzerland	For		For	
BeiGene Ltd.	6160	1940732	28-Apr-2025	2	Amend Articles of Association	For		For	
BeiGene Ltd.	6160	1940732	28-Apr-2025	3	Approve Ernst & Young AG as Auditors and Authorize Board to Fix Their Remuneration	For		For	
Bachem Holding AG	BANB	1921735	30-Apr-2025	1.1	Accept Financial Statements and Statutory Reports	For		For	
Bachem Holding AG	BANB	1921735	30-Apr-2025	1.2	Approve Remuneration Report	For		Against	
Bachem Holding AG	BANB	1921735	30-Apr-2025	1.3	Approve Sustainability Report	For		For	
Bachem Holding AG	BANB	1921735	30-Apr-2025	2	Approve Discharge of Board and Senior Management	For		For	
Bachem Holding AG	BANB	1921735	30-Apr-2025	3	Approve Allocation of Income and Dividends of CHF 0.43 per Share and CHF 0.42 per Share from Capital Contribution Reserves	For		For	
Bachem Holding AG	BANB	1921735	30-Apr-2025	4.1	Approve Remuneration of Directors in the Amount of CHF 750,000	For		For	
Bachem Holding AG	BANB	1921735	30-Apr-2025	4.2	Approve Remuneration of Executive Committee in the Amount of CHF 2.9 Million	For		For	
Bachem Holding AG	BANB	1921735	30-Apr-2025	5.1	Reelect Kuno Sommer as Director and Board Chair	For		Against	
Bachem Holding AG	BANB	1921735	30-Apr-2025	5.2	Reelect Nicole Hoetzer as Director	For		Against	
Bachem Holding AG	BANB	1921735	30-Apr-2025	5.3	Reelect Helma Wennemers as Director	For		Against	
Bachem Holding AG	BANB	1921735	30-Apr-2025	5.4	Reelect Steffen Lang as Director	For		Against	

Company	Ticker	Meeting ID	Meeting Date	Proposal #	Proposal Text	Management Recommendation	Policy Recommendation	Vote Instruction	Rationale
Bachem Holding AG	BANB	1921735	30-Apr-2025	5.5	Reelect Alex Faessler as Director	For		Against	
Bachem Holding AG	BANB	1921735	30-Apr-2025	5.6	Elect Simon Fedele as Director	For		Against	
Bachem Holding AG	BANB	1921735	30-Apr-2025	6.1	Reappoint Kuno Sommer as Member of the Compensation Committee	For		Against	
Bachem Holding AG	BANB	1921735	30-Apr-2025	6.2	Reappoint Nicole Hoetzer as Member of the Compensation Committee	For		Against	
Bachem Holding AG	BANB	1921735	30-Apr-2025	6.3	Reappoint Alex Faessler as Member of the Compensation Committee	For		Against	
Bachem Holding AG	BANB	1921735	30-Apr-2025	7	Ratify Forvis Mazars SA as Auditors	For		For	
Bachem Holding AG	BANB	1921735	30-Apr-2025	8	Designate Paul Wiesli as Independent Proxy	For		For	
Bachem Holding AG	BANB	1921735	30-Apr-2025	9	Transact Other Business (Voting)	For		Against	
Boston Scientific Corporation	BSX	1942496	01-May-2025	1a	Elect Director Yoshiaki Fujimori	For		For	
Boston Scientific Corporation	BSX	1942496	01-May-2025	1b	Elect Director David C. Habiger	For		For	
Boston Scientific Corporation	BSX	1942496	01-May-2025	1c	Elect Director Edward J. Ludwig	For		For	
Boston Scientific Corporation	BSX	1942496	01-May-2025	1d	Elect Director Michael F. Mahoney	For		For	
Boston Scientific Corporation	BSX	1942496	01-May-2025	1e	Elect Director Jessica L. Mega	For		For	
Boston Scientific Corporation	BSX	1942496	01-May-2025	1f	Elect Director Susan E. Morano	For		For	
Boston Scientific Corporation	BSX	1942496	01-May-2025	1g	Elect Director Cheryl Pegus	For		For	
Boston Scientific Corporation	BSX	1942496	01-May-2025	1h	Elect Director John E. Sununu	For		For	
Boston Scientific Corporation	BSX	1942496	01-May-2025	1i	Elect Director David S. Wichmann	For		For	
Boston Scientific Corporation	BSX	1942496	01-May-2025	1j	Elect Director Ellen M. Zane	For		For	
Boston Scientific Corporation	BSX	1942496	01-May-2025	2	Advisory Vote to Ratify Named Executive Officers' Compensation	For		For	

Company	Ticker	Meeting ID	Meeting Date	Proposal #	Proposal Text	Management Recommendation	Policy Recommendation	Vote Instruction	Rationale
Boston Scientific Corporation	BSX	1942496	01-May-2025	3	Ratify Ernst & Young LLP as Auditors	For		For	
Boston Scientific Corporation	BSX	1942496	01-May-2025	4	Adopt Simple Majority Vote	None		For	
Eli Lilly and Company	LLY	1943886	05-May-2025	1a	Elect Director Ralph Alvarez	For		For	
Eli Lilly and Company	LLY	1943886	05-May-2025	1b	Elect Director Mary Lynne Hedley	For		For	
Eli Lilly and Company	LLY	1943886	05-May-2025	1c	Elect Director Kimberly H. Johnson	For		For	
Eli Lilly and Company	LLY	1943886	05-May-2025	1d	Elect Director Juan R. Luciano	For		For	
Eli Lilly and Company	LLY	1943886	05-May-2025	2	Advisory Vote to Ratify Named Executive Officers' Compensation	For		For	
Eli Lilly and Company	LLY	1943886	05-May-2025	3	Ratify Ernst & Young LLP as Auditors	For		For	
Eli Lilly and Company	LLY	1943886	05-May-2025	4	Declassify the Board of Directors	For		For	
Eli Lilly and Company	LLY	1943886	05-May-2025	5	Eliminate Supermajority Vote Requirement	For		For	
BeiGene Ltd.	6160	1955317	21-May-2025	1	Elect Director Anthony C. Hooper	For		For	
BeiGene Ltd.	6160	1955317	21-May-2025	2	Elect Director Ranjeev Krishana	For		For	
BeiGene Ltd.	6160	1955317	21-May-2025	3	Elect Director Xiaodong Wang	For		For	
BeiGene Ltd.	6160	1955317	21-May-2025	4	Elect Director Qingqing Yi	For		For	
BeiGene Ltd.	6160	1955317	21-May-2025	5	Elect Director Shalini Sharp	For		For	
BeiGene Ltd.	6160	1955317	21-May-2025	6	Ratify Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as Auditors	For		For	
BeiGene Ltd.	6160	1955317	21-May-2025	7	Authorize Board to Fix Remuneration of Auditors	For		For	
BeiGene Ltd.	6160	1955317	21-May-2025	8	Authorize the Board of Directors to Issue, Allot, or Deal with Unissued Ordinary Shares and/or American Depositary Shares	For		Against	

Company	Ticker	Meeting ID	Meeting Date	Proposal #	Proposal Text	Management Recommendation	Policy Recommendation	Vote Instruction	Rationale
BeiGene Ltd.	6160	1955317	21-May-2025	9	Authorize Share Repurchase Program	For		For	
BeiGene Ltd.	6160	1955317	21-May-2025	10	Approve Connected Person Placing Authorization I	For		Against	
BeiGene Ltd.	6160	1955317	21-May-2025	11	Advisory Vote to Ratify Named Executive Officers' Compensation	For		Against	
BeiGene Ltd.	6160	1955317	21-May-2025	12	Adjourn Meeting	For		Against	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	1a	Elect Director Marc N. Casper	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	1b	Elect Director Nelson J. Chai	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	1c	Elect Director Ruby R. Chandy	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	1d	Elect Director C. Martin Harris	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	1e	Elect Director Tyler Jacks	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	1f	Elect Director Jennifer M. Johnson	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	1g	Elect Director R. Alexandra Keith	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	1h	Elect Director Karen S. Lynch	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	1i	Elect Director James C. Mullen	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	1j	Elect Director Debora L. Spar	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	1k	Elect Director Scott M. Sperling	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	1l	Elect Director Dion J. Weisler	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	2	Advisory Vote to Ratify Named Executive Officers' Compensation	For		Against	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	3	Ratify PricewaterhouseCoopers LLP as Auditors	For		For	
Thermo Fisher Scientific Inc.	TMO	1951938	21-May-2025	4	Amend Right to Call Special Meeting	Against		Against	
Align Technology, Inc.	ALGN	1951723	21-May-2025	1.1	Elect Director Kevin T. Conroy	For		For	

Reporting Period: 30-Sep-2024 to 30-Sep-2025

Company	Ticker	Meeting ID	Meeting Date	Proposal #	Proposal Text	Management Recommendation	Policy Recommendation	Vote Instruction	Rationale
Align Technology, Inc.	ALGN	1951723	21-May-2025	1.2	Elect Director Kevin J. Dallas	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	1.3	Elect Director Joseph M. Hogan	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	1.4	Elect Director Joseph Lacob	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	1.5	Elect Director C. Raymond Larkin, Jr.	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	1.6	Elect Director George J. Morrow	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	1.7	Elect Director Anne M. Myong	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	1.8	Elect Director Mojdeh Poul	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	1.9	Elect Director Andrea L. Saia	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	1.10	Elect Director Susan E. Siegel	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	2	Advisory Vote to Ratify Named Executive Officers' Compensation	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	3	Ratify PricewaterhouseCoopers LLP as Auditors	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	4	Eliminate Supermajority Vote Requirement	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	5	Amend Omnibus Stock Plan	For		For	
Align Technology, Inc.	ALGN	1951723	21-May-2025	6	Provide Right to Call a Special Meeting at a 25 Percent Ownership Threshold	For		Against	
Align Technology, Inc.	ALGN	1951723	21-May-2025	7	Provide Right to Call a Special Meeting at a 10 Percent Ownership Threshold	Against		For	
UnitedHealth Group Incorporated	UNH	1958884	02-Jun-2025	1a	Elect Director Charles Baker	For		For	
UnitedHealth Group Incorporated	UNH	1958884	02-Jun-2025	1b	Elect Director Timothy Flynn	For		For	
UnitedHealth Group Incorporated	UNH	1958884	02-Jun-2025	1c	Elect Director Paul Garcia	For		For	

Reporting Period: 30-Sep-2024 to 30-Sep-2025

Company	Ticker	Meeting ID	Meeting Date	Proposal #	Proposal Text	Management Recommendation	Policy Recommendation	Vote Instruction	Rationale
UnitedHealth Group Incorporated	UNH	1958884	02-Jun-2025	1d	Elect Director Kristen Gil	For		For	
UnitedHealth Group Incorporated	UNH	1958884	02-Jun-2025	1e	Elect Director Stephen Hemsley	For		For	
UnitedHealth Group Incorporated	UNH	1958884	02-Jun-2025	1f	Elect Director Michele Hooper	For		For	
UnitedHealth Group Incorporated	UNH	1958884	02-Jun-2025	1g	Elect Director F. William McNabb, III	For		For	
UnitedHealth Group Incorporated	UNH	1958884	02-Jun-2025	1h	Elect Director Valerie Montgomery Rice	For		For	
UnitedHealth Group Incorporated	UNH	1958884	02-Jun-2025	1i	Elect Director John Noseworthy	For		For	
UnitedHealth Group Incorporated	UNH	1958884	02-Jun-2025	2	Advisory Vote to Ratify Named Executive Officers' Compensation	For		Against	
UnitedHealth Group Incorporated	UNH	1958884	02-Jun-2025	3	Ratify Deloitte & Touche LLP as Auditors	For		For	
UnitedHealth Group Incorporated	UNH	1958884	02-Jun-2025	4	Submit Severance Agreement to Shareholder Vote	Against		Against	
Globus Medical, Inc.	GMED	1962930	04-Jun-2025	1a	Elect Director David C. Paul	For		Withhold	
Globus Medical, Inc.	GMED	1962930	04-Jun-2025	1b	Elect Director Daniel T. Lemaitre	For		For	
Globus Medical, Inc.	GMED	1962930	04-Jun-2025	1c	Elect Director Leslie V. Norwalk	For		For	
Globus Medical, Inc.	GMED	1962930	04-Jun-2025	1d	Elect Director Ann D. Rhoads	For		Withhold	
Globus Medical, Inc.	GMED	1962930	04-Jun-2025	2	Amend Omnibus Stock Plan	For		Against	
Globus Medical, Inc.	GMED	1962930	04-Jun-2025	3	Ratify Deloitte & Touche LLP as Auditors	For		For	
Globus Medical, Inc.	GMED	1962930	04-Jun-2025	4	Advisory Vote to Ratify Named Executive Officers' Compensation	For		For	
Globus Medical, Inc.	GMED	1962930	04-Jun-2025	5	Advisory Vote on Say on Pay Frequency	One Year		One Year	

PARAMETERS

Location(s): All Locations
Account Group(s): All Account Groups
Institution Account(s): Kieger Sustainable Healthcare Fund
Custodian Account(s): All Custodian Accounts
ADR Meetings: All Meetings
Client Covered: – None –
Contrary Votes: All Votes
Date Format: DD-MMM-YYYY
ISS Governance QualityScore < =: None
ISS Governance QualityScore > =: None
Highlighted Meetings: Include Contested and High Risk Meeting Details
Industry Sectors: All Sectors
Market Cap (USD) < =: None
Market Cap (USD) > =: None
Markets: All Markets
Meeting ID's: All Meeting ID's
Meeting Types: All Meeting Types
PoA Markets: All Markets
Proposal Proponents: All Proponents
Recommendations: All Recommendations
Record Date Markets: All Markets
Reregistration Meetings: Exclude Reregistration Meetings
Shareblocking Markets: All Markets
Speciality Policy: - None -
Vote Instructions: All Instructions
Voting Policies: None
Zero (0) Share Ballots: Exclude 0 Share Ballots
Account Group Watchlist: None
Account Watchlist: None
Country Watchlist: None
Issuer Watchlist: None
Proposal Code Watchlist: None

This document and all of the information contained in it, including without limitation all text, data, graphs and charts (collectively, the "Information") is the property of Institutional Shareholder Services Inc., its subsidiary, ISS Corporate Services, Inc., or in some cases third party suppliers (collectively "ISS"). The Information may not be reproduced or disseminated in whole or in part without prior written permission of ISS.

Information regarding the holdings and other data specific to the named recipient of this report (the "Recipient"), has been compiled from the records of only the asset manager(s) who use ISS' proxy advisory/voting services and who have authorized ISS to include the Recipient's data in this report. ISS believes this data to be reliable but cannot guarantee its accuracy.

The Information has not been submitted to, nor received approval from, the United States Securities and Exchange Commission or any other regulatory body. None of the Information constitutes an offer to sell (or a solicitation of an offer to buy), or a promotion or recommendation of, any security, financial product or other investment vehicle or any trading strategy, nor a solicitation of a proxy, and ISS does not endorse, approve or otherwise express any opinion regarding any issuer, securities, financial products or instruments or trading strategies.

Issuers mentioned in this product may have purchased self-assessment tools and publications from ISS Corporate Services, Inc. ("ICS"), a wholly owned subsidiary of ISS, or ICS may have provided advisory or analytical services to the issuer. No employee of ICS played a role in the preparation of the content of this product. Any issuer that is mentioned in this document may be a client of ISS or ICS, or may be the parent of, or affiliated with, a client of ISS or ICS. If you are an ISS institutional client, you may inquire about any issuer's use of products and services from ICS by emailing disclosure@issgovernance.com.